Patents by Inventor Robert Kiss

Robert Kiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210306281
    Abstract: Methods and devices for creating and operating a combined network and computational slice instance (NCSI) in a Multi-access Edge Computing (MEC) scenario. Communication and computational resources may be reserved by a NCSI controller for the NCSI. The communication resources may include network slices and the computational resources may include MEC computational resources of one or more MEC servers. The reserved resources may be selected based on quality of service (QoS) requirements of UEs that will utilize the NCSI. During operation, reserved resources for the NCSI may be dynamically renegotiated based on an aggregate load of the NCSI, the QoS of data traffic, and/or updated QoS requirements of the UEs.
    Type: Application
    Filed: March 23, 2021
    Publication date: September 30, 2021
    Inventors: Mikhail Vilgelm, Babar Qaisrani, Biljana Badic, Christian Drewes, Krisztian Kiss, Matthias Sauer, Vijay Venkataraman, Ralph Hasholzner, Robert Zaus, Teck Yang Lee
  • Patent number: 9181265
    Abstract: Novel phenazine derivatives of formula (I) are disclosed. In particular, substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines are disclosed. The compounds can be used as anti-angiogenic and/or anti-tumor agents.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 10, 2015
    Assignees: UNIVERSITE CATHOLIQUE DE LOUVAIN, UNIVERSITE LIBRE DE BRUXELLES
    Inventors: Olivier Feron, Olivier Riant, Robert Kiss, Joelle Leclercq, Gabrielle Chataigne, Nicolas Vandelaer, Carole Lamy
  • Patent number: 9168247
    Abstract: The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: October 27, 2015
    Assignees: FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX, UNIVERSITE LIBRE BRUXELLES
    Inventors: Raphael Frederick, Bernard Masereel, Jeremy Reniers, Johan Wouters, Celine Bruyere, Robert Kiss, Céline Anne Marie Michelle Meinguet, Véronique Emmanuelle Julie Mathieu
  • Patent number: 8772265
    Abstract: The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumor and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: July 8, 2014
    Assignees: Universite Libre de Bruxelles, Universite de Liege
    Inventors: Philippe Neven, Didier Serteyn, Robert Kiss, Veronique Mathieu, Didier Cataldo, Natacha Rocks, Eva Scheer
  • Publication number: 20140005220
    Abstract: The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.
    Type: Application
    Filed: June 24, 2011
    Publication date: January 2, 2014
    Applicants: UNIVERSITE LIBRE DE BRUXELLES, FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX
    Inventors: Raphael Frederick, Bernard Masereel, Jeremy Reniers, Johan Wouters, Celine Bruyere, Robert Kiss
  • Publication number: 20130289030
    Abstract: The present invention is directed to novel compounds of formula I and their use as anti-angiogenic agents and anti-cancer agents.
    Type: Application
    Filed: December 22, 2011
    Publication date: October 31, 2013
    Applicants: UNIVERSITE LIBRE DE BRUXELLES, UNIVERSITE CATHOLIQUE DE LOUVAIN
    Inventors: Olivier Feron, Olivier Riant, Robert Kiss, Joelle Leclercq, Gabrielle Chataigne, Nicolas Vandelaer, Carole Lamy
  • Publication number: 20130116273
    Abstract: The invention provides novel beta-carboline derivatives of formulae (Ia) and (Ib) useful in the treatment of proliferative disorders including cancer, intermediates used in their preparation, processes for preparing the same and uses thereof.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 9, 2013
    Applicants: UNIVERSITE LIBRE DE BRUXELLES, FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX
    Inventors: Raphael Frederick, Bernard Masereel, Jeremy Reniers, Johan Wouters, Celine Bruyere, Robert Kiss
  • Publication number: 20130053347
    Abstract: The present invention relates to the biology and mechanism of action of the naturally occurring compound Narciclasine, especially as an anti-cancer agent for brain tumors. The invention provides new insights on the target molecule of Amaryllidaceae isocarbostyril derivatives as for example Narciclasine and provides new prodrugs of these Amaryllidceae isocabostyril constituents for treating cancer, specifically cancers or tumors located in the brain.
    Type: Application
    Filed: May 3, 2010
    Publication date: February 28, 2013
    Applicant: Universite Libre de Bruxelles
    Inventors: Veronique Mathieu, Gwendoline Van Goietsenoven, Jacques Dubois, Florence Lefranc-Kiss, Laurent Ingrassia, Robert Kiss
  • Publication number: 20110280940
    Abstract: The invention relates to the medical field, more precisely in the field of anti-cancer treatment and treatment of Alzheimer's disease, Parkinson's disease or Pick's disease or for ameliorating symptoms of Down syndrome, providing newly synthesised multi-vanilloyl derivative compounds and their use in the treatment of said disorders.
    Type: Application
    Filed: October 13, 2009
    Publication date: November 17, 2011
    Inventors: Robert Kiss, Jacques Dubois, Jean Neve, Delphine Lamoral-Theys, Francois Dufrasne, Laurent Pottier
  • Publication number: 20110257126
    Abstract: The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumour and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: May 26, 2009
    Publication date: October 20, 2011
    Applicants: Universite de Liege, Universite Libre de Bruxelles
    Inventors: Philippe Neven, Didier Serteyn, Jacques Delarge, Eva Scheer, Robert Kiss, Veronique Mathieu, Didier Cataldo, Natacha Rocks
  • Patent number: 7981875
    Abstract: Compounds and pharmaceutical compositions which include 2? oxo-voruscharin and derivatives are disclosed. The compounds and pharmaceutical compositions are useful in methods of treating cancer, particularly pancreatic cancer.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: July 19, 2011
    Assignees: Unibioscreen S.A., Universite Libre de Bruxelles
    Inventors: Eric Van Quaquebeke, Jean-Claude Braekman, Gentiane Simon, Pierre Guissou, Odile Germaine Nacoulma, Janique Dewelle, Francis Darro, Robert Kiss
  • Patent number: 7964575
    Abstract: The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: June 21, 2011
    Assignees: Universite Libre de Bruxelles, Universite Catholique de Louvain
    Inventors: Isabelle Camby, Patrick Henriet, Florence Lefranc, Pierre Courtoy, Robert Kiss
  • Patent number: 7741337
    Abstract: The present invention is directed to azonafide derivatives obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of cancer.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: June 22, 2010
    Assignee: Unibioscreen S.A.
    Inventors: Eric Van Quaquebeke, Jérôme Tuti, Laurent Van den Hove, Robert Kiss, Francis Darro
  • Publication number: 20100120891
    Abstract: The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma.
    Type: Application
    Filed: March 9, 2006
    Publication date: May 13, 2010
    Applicants: UNIVERSITE LIBRE DE BRUXELLES, UNIVERSITE CATHOLIQUE DE LOUVAIN
    Inventors: Isabelle Camby, Patrick Henriet, Florence Lefranc, Pierre Courtoy, Robert Kiss
  • Publication number: 20100076005
    Abstract: Isocarbostyril alkaloid derivatives having an anti-proliferative and anti-migratory activities are disclosed. In particular, compounds of formula (I) or (II), as well as stereoisomers, tautomers, racemates, prodrugs, metabolites thereof, pharmaceutically acceptable salt and/or solvate are encompassed which are useful in the treatment and prophylaxis of cancer. Methods of preparation are also disclosed.
    Type: Application
    Filed: October 12, 2007
    Publication date: March 25, 2010
    Applicant: Unibioscreen SA
    Inventors: Laurent Ingrassia, Lise Wlodarczak, Stephanie Thomas, Eric Van Quaquebeke, Laurent Van den Hove, Robert Kiss, Francis Darro
  • Publication number: 20100068198
    Abstract: Targeting of select subunits of the Na+,K+-ATPase is described, and especially the alpha-1 subunit and/or the alpha-3 subunit. Antisense agents, agents capable of causing RNA interference that can reduce the expression of Na+,K+-ATPase, and antibodies and antibody fragments and derivatives specific for Na+,K+-ATPase are useful as reagents and pharmaceutical formulations for the treatment of proliferative diseases, such as tumours and cancers. Methods and kits are also described.
    Type: Application
    Filed: November 9, 2006
    Publication date: March 18, 2010
    Applicant: Unibioscreen S.A.
    Inventors: Tatjana Mijatovic, Eric Van Quaquebeke, Nancy Denève, Laurent Van den Hove, Francis Darro, Robert Kiss
  • Publication number: 20090232907
    Abstract: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast with the compounds described herein alone and in combination with antineoplastic agents.
    Type: Application
    Filed: November 17, 2008
    Publication date: September 17, 2009
    Applicant: Unibioscreen S.A.
    Inventors: Eric Van Quaquebeke, Gentiane Simon, Mohamed El Yazidi, Jerome Tuti, Laurent Van Den Hove, Francis Darro, Robert Kiss
  • Publication number: 20090221628
    Abstract: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast with the compounds described herein alone and in combination with antineoplastic agents.
    Type: Application
    Filed: November 17, 2008
    Publication date: September 3, 2009
    Applicant: Unibioscreen S.A.
    Inventors: Eric Van Quaquebeke, Gentiane Simon, Mohamed El Yazidi, Jerome Tuti, Laurent Van Den Hove, Francis Darro, Robert Kiss
  • Publication number: 20090186915
    Abstract: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast with the compounds described herein alone and in combination with antineoplastic agents.
    Type: Application
    Filed: November 17, 2008
    Publication date: July 23, 2009
    Applicant: Unibioscreen S. A.
    Inventors: Eric Van Quaquebeke, Gentiane Simon, Mohamed El Yazidi, Jerome Tuti, Laurent Van Den Hove, Francis Darro, Robert Kiss
  • Publication number: 20090118321
    Abstract: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods for making such derivatives through hydrolysis of known compounds.
    Type: Application
    Filed: May 7, 2007
    Publication date: May 7, 2009
    Applicant: Unibioscreen S.A.
    Inventors: Eric Van Quaquebeke, Gentiane Simon, Mohamed El Yazidi, Jerome Tuti, Laurent Van den Hove, Francis Darro, Robert Kiss